Home

Insights

TTK Healthcare Ltd P/E Ratio

TTK Healthcare Ltd P/E Ratio

download
stocks purchased

₹ 0.0 Cr

Volume transacted

stocks purchased

0.2 K

stocks traded

Image

TTK Healthcare Ltd

NSE: TTKHLTCARE

PE

32.9

Last updated : 20 Jun 06:16 AM

Key Highlights

    The P/E Ratio of TTK Healthcare Ltd is 32.9 as of 20 Jun 06:16 AM .a1#The P/E Ratio of TTK Healthcare Ltd changed from 39.3 on March 2019 to 2.3 on March 2023 . This represents a CAGR of -43.32% over 5 years. a1#The Latest Trading Price of TTK Healthcare Ltd is ₹ 1482 as of 20 Jun 11:39 .a1#The PE Ratio of Diversified Industry has changed from 26.5 to 21.1 in 5 years. This represents a CAGR of -4.46%a1# The PE Ratio of Automobile industry is 11.3. The PE Ratio of Diversified industry is 36.6. The PE Ratio of Finance industry is 31.6. The PE Ratio of IT - Software industry is 28.9. The PE Ratio of Retail industry is 142.7. The PE Ratio of Textiles industry is 7.2. In 2024a1#The Market Cap of TTK Healthcare Ltd changed from ₹ 958.96 crore on March 2019 to ₹ 1461 crore on March 2023 . This represents a CAGR of 8.79% over 5 years. a1#The Revenue of TTK Healthcare Ltd changed from ₹ 799 crore to ₹ 197.11 crore over 8 quarters. This represents a CAGR of -50.33% a1#The EBITDA of TTK Healthcare Ltd changed from ₹ 610.14 crore to ₹ 28.48 crore over 8 quarters. This represents a CAGR of -78.39% a1#The Net Profit of TTK Healthcare Ltd changed from ₹ 600.86 crore to ₹ 18.27 crore over 8 quarters. This represents a CAGR of -82.56% a1#The Dividend Payout of TTK Healthcare Ltd changed from 28.99 % on March 2019 to 2.21 % on March 2023 . This represents a CAGR of -40.24% over 5 years. a1#

Open Demat Account

Lead form image

+91

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

*By signing up you agree to our terms & conditions

×

P/E Ratio Over Time

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

P/E Ratio Over Time

Period
Mar '1939.3
Mar '2037.5
Mar '2115.1
Mar '2228.2
Mar '232.3

Fundamental Metrics

Market Cap

2,067 Cr

EPS

44.5

P/E Ratio (TTM) *

32.9

P/B Ratio (TTM) *

2.1

Day’s High

1490.0

Day’s Low

1467.05

DTE *

0.0

ROE *

6.3

52 Week High

1725.85

52 Week Low

1117.05

ROCE *

8.5

* All values are consolidated

Last Updated time: 20 Jun 06:16 AM

* All values are consolidated

Last Updated time: 20 Jun 06:16 AM

Image

TTK Healthcare Ltd

NSE: TTKHLTCARE

PRICE

1482.45

19.30 (1.32%)

stock direction

Last updated : 20 Jun 11:39

×

PRICE

The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.

Share price Over Time

1M

1Y

3Y

5Y

* All values are in Rupees

SWOT Analysis Of TTK Healthcare Ltd

Strength

1

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

Asset Value vs Market Value

Market Value

2,067

Asset Value

1,071

0.9 X

Value addition

* All values are in Rupees

PE Ratio Over Market Cap

Company NamePEMarket Cap (INR Cr.)
3M India Ltd7141,623
Swan Energy Ltd6820,577
DCM Shriram Ltd3816,195
Nava Ltd1210,494
Quess Corp Ltd309,055
TTK Healthcare Ltd322,067

Key Valuation Metric

Earnings

62 Cr

32.9 X

PE Ratio

Market Cap

₹2067Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio

PS Ratio

PB Ratio

Earnings

62 Cr

32.9 X

PE Ratio

Market Cap

₹2067Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Diversified Industry over time

PE Ratio of Top Sectors

×

Market Cap Over Time

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Market Cap Over Time

Period
Mar '19959
Mar '20462
Mar '21699
Mar '221172
Mar '231461

* All values are a in crore

×

Revenue Over Time

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Revenue Over Time

Period
Jun '22799
Sep '22183
Dec '22194
Mar '23196
Jun '23217
Sep '23202
Dec '23200
Mar '24197

* All values are a in crore

×

EBITDA Over Time

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

EBITDA Over Time

Period
Jun '22610
Sep '2217
Dec '2220
Mar '2327
Jun '2325
Sep '2326
Dec '2321
Mar '2428

* All values are a in crore

×

Net Profit Over Time

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Net Profit Over Time

Period
Jun '22601
Sep '2210
Dec '2212
Mar '2317
Jun '2316
Sep '2316
Dec '2313
Mar '2418

* All values are a in crore

×

Dividend Payout Over Time

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Dividend Payout Over Time

Period
Mar '1929
Mar '2034
Mar '2118
Mar '2234
Mar '232

* All values are a in %

About TTK Healthcare Ltd

About TTK Healthcare Ltd

    TTK Healthcare Limited, a TTK Group Company was incorporated in May 1958 as Orient Pharma and later renamed as TTK Pharma in Nov '81. The Company is the owner of famous Woodwards Gripewater brand. The Company operate into five main Strategic Business Units namely, Pharmaceuticals, Consumer Products, Medical Devices, Foods and Protective Devices divisions. It is engaged into Animal Welfare Products, Consumer Products, Medical Devices, Protective Devices and Foods Businesses. In 1992, the company came out with a rights issue at a premium of Rs 35 aggregating Rs 5.81 cr to finance long-term working capital needs, normal capital expenditure, and product promotion. Products of TTK Healthcare include cardiac care systems, blood management systems, renal care systems, hospital accessories, antibiotics, Woodwards gripe water, animal medicines, etc. It also has a consumer products and food division manufacturing kiwi shoe polishes, snacks, etc. The company has collaborations with a number of foreign corporations such as London International, Kali-Chemi, Germany; Hatu-ICO, Spain; Nicholas Kiwi, US, etc. The products of the company are exported to the UK, Egypt, the US, Germany, Singapore, Malaysia, Carribean countries, etc. The Pallavaram plant of the company has been accredited with the ISO 14002 certification by the Bureau of Indian Standards. Also, one of the group companies, TT Maps and Publications was merged with TTK Pharma in 1993. The company faced some rough weather in Jul.'95 when the MRTPC ordered an inquiry against it for allegedly directing its whole-salers to keep a minimum stock of the company's products and defining their area of operations. During 1996-97, the company has tied up with M/s Mentholatum India Pvt Ltd. During the year 1999-2000, as a part of the restructuring programme, the paper divison of the company has been disposed off and the merger of TTK Biomed has been approved by the Hon'ble High Court Of Madras with retrospective effect from July 1, 1999. In 2000-01, the company has vacated the bulk drug business segment by disposing of the Bulk Drugs & Formulations facility at Hyderabad. The High Court, Madras has approved the scheme of amlagamation between TTK Medical Devices Ltd. and the company. During the financial year 2003-04,the Heart Valve division of the company has been awarded ISO 9001-2000 Certification by RWTUV,Germany. Under the Ethical Products Division, Company launched three new products viz., OFORD-LB (Ofloxcacin with Omidazole & Lactobacillus - a broad spectrum antimicrobial); NUROBEST (Methylcobalamin with Alpha Lipoic Acid - to prevent and treat neuropathy); and OSSOPAN-ALFA (Calcium with Alfacalcidol - to prevent and treat Osteoporosis) DURING 2004. During November 2004, a Strategic Partner was inducted into M/s.TTK Healthcare Services Private Limited, the Subsidiary of Company to infuse further capital into this entity. Consequent to allotment of shares to the said Strategic Partners by TTK Healthcare Services Private Limited, the Shareholding of Company in the said Subsidiary reduced from 56.33% to 35.06% during the year 2004-05 and consequently, TTK Healthcare Services Private Limited ceased to be the Subsidiary of Company. During 2005, the Company launched OSSOGEMS (Chewable Milk Qalcium) and re-launched ARTHRID (an anti-Arthritis Formulation). Under the Animal Welfare Division, three new products viz., LYSETIK (Deltamethrin), ENROBEST (Enrofloxacin) and TT ZYME (Cocktail Enzyme) have been recently launched. To bring about an enhanced focus on the Herbal'Products Segment, Company launched a New Marketing Division VENTURA. It expanded the Animal Welfare Division operations in Punjab and Uttar Pradesh. The Company launched Moisturizer under the Brand 'Eva Nourish' during the year 2006. It launched a range of Pain Management Products under the brand name DOLOBEST and three new products viz., CALCITRIOL (a Calcium Supplement), RABULCER-D (an AntiUlcerant) and LEVOCOLD (an Anti-cold preparation) under the Ethical Products Division. It launched 3 new products viz., PROTOGEN-G (Protein Supplement). DELiVERA (Moisturizing Cream) and CLIMACTER (forMenopausal Symptoms) under Ventura Division. It launched quality soap for babies under the brand 'Woodward's Baby Bath' in two variants in Tamil Nadu and Andhra Pradesh under the Consumer Products Division. It launched BLOX (Toxin Binder), TEFROLI FORTE PET (Liver Tonic) and TT-CEF (Cephalosporin Injection) under the Animal Welfare business division. During the year 2007, the Company launched three new products viz., LYCO-Q (Male Infertility Formulation), ARTHRID OIL (Anti-Arthritis Formulation) and UTRONORM FORTE (Fortified Version of Poly Herbal Uterine Tonic) under the Ventura Division; launched a new product viz., IMMULAR (Herbal Immuno Modulator) under the Animal Welfare Division. It launched a Moisturizer and a Lip Balm under the EVA brand. During year 2008, the Company launched five new products viz., Lycoprost-SP (for treating prostate enlargement); Dolout-P (pain killer); Krease (pancreatin enzyme); Elcarim IQ (IQ enhancer); and Calzibor (calcium supplement) under the Ventura Division. Animal Welfare Division launched four new products viz., Prophytase (enzyme preparation); Rumibest (digestive powder); Lavitone Liquid & Lavitone-H Injection (vitamin supplement); and Melobest-P (antiinflammatory / analgesic Injection). The business undertaking of Medical Devices Division at Waluj was sold during the year. During year 2009, the Company launched four formulations viz., LR Zin, LR Zin Forte, CCQ 25 and CCQ 50 into the Ventura Division. Melobest Inj. and Melobest Bolus (Antiinflammatory/Analgesic) were added to the range into the Animal Welfare Division. Fantasy Talc was added to the talcum powder range. Further, EVA Sun Shield got launched under the skin care category. Under the Good Home Range, Room Spray and new variants of Scrubbers such as Large, 2-in-one, Xtra Tough, etc., were introduced into the Consumer Products Division. In 2010, P-Biotic (a combination of Pre & Probiotic), Urofit (an alkalizer for managing renal stones), Ossopan BMD (a mineral fortified calcium preparation for the treatment of osteoporosis) and Folibest DHA (folic acid and iodine based supplement) were launched into the Ethical Products Division. Company enhanced its presence in the anti-infertility segment with the launch of three new formulations viz., Aromatin (Letrozole), ChromiNac-A (a combination of Chromium Picolinate and N-Acetyl Cysteine) and Carni-Q (a combination of L-Carnitine and Co-enzyme Q10). Increlac (Herbal Galactagogue), Gestaforte Plus Bolus (Fertility Promoter), Blox OA (Toxin Binder with organic acids) were the new products added to the range into the Animal Welfare Division Buisness during the year 2009-10. The Company acquired the Manufacturing Facility for Orthopaedic Implants including Total Knee Replacement System from Invicta Meditek Limited in July 2009 by getting into the Ortho Segment. The Pellet (Pappad) manufacturing line imported from M/s Fen, Italy was erected and commissioned in November, 2010 into the Foods Business. The Lip Balm was introduced into the Consumer Products Division during the year 2010-11. In November 2012, TTK Protective Devices Limited launched a new brand of Condom 'Skore into the Consumer Products Business division. A small manufacturing facility was set up for manufacturing Instrumentation Sets at Chromepet, Chennai into the Ortho Division. The Fen make Pellet (Pappad) Manufacturing line acquired from M/s McFills, Ahmedabad was commissioned and both the Fen Lines and the old refurbished Pavan Lines started working at full capacity into the Foods Business Division. Thereafter, the Company launched retail packs of Ready-to-fry Snack Pellets (Pappads) in Andhra Pradesh, during First Quarter of 2013-14. The Company embarked upon growing projects for Foods Business including the new manufacturing facility set up in Jaipur in 2013-14. It introduced a number of products in Anti-Ulcerant, Respiratory, Infertility and Gynaecology segments to consolidate into these therapeutic segments of Ethical Products Division (EPD) & Ventura Division during 2015-16. During the year 2016-17, Company introduced a couple of line extensions under 'Ossopan' brand to strengthen the Calcium Segment. During the year 2016-17, ompany made an investment of Rs.3.40 lakhs in M/s Renew Wind Power (AP) Private Limited, in connection with purchase of wind power, by way of subscription to the issue of 3,400 Equity Shares of face value of Rs.10 each at a price of Rs.100 per Equity Share. Subsequently, 2,500 Equity Shares were transferred to M/s Renew Wind Power (Karnataka Three) Private Limited at a price of Rs.100 each, thus holding the balance 900 Equity Shares of Rs.10 each (Rs.0.90 lakhs) as on 31st March, 2017. During year 2017-18, TTK Protective Devices Limited and its Wholly Owned Subsidiary TSL Techno Services Limited was merged with the Company through the Scheme of Amalgamation dated 15th December, 2017, where the Appointed Date of the Scheme was 1st April, 2012. Consequent to the above, the erstwhile TTK Protective Devices Limited became a Division of Company and for operational convenience, which was named as 'Protective Devices Division'. The development and testing of Cementless Hip Implant was commissioned into the Ortho Division during the year 2018-19. During the year 2019-20, the Company had bifurcated the Ventura Division into- (i) Ventura - Gynaec; and (ii) Ventura - Fertility. Jessica QF (a novel pregnancy supplement), Sensipreg SR (progesterone), Erafos (Fosfomycin) and Pufer (a Haematinic) was newly launched in 2019-20. The packaging of the EVA Deodorant was fully revamped with a two tone colour scheme and also complete change in the graphics of the pack. This new pack was launched in March, 2019. Skore brand was extended with pleasure aids like Orgasmic Gel for women, Vibrating Rings as well as Pheromone Activating Spray for men. During the year 2020-21, the Company launched products such as Bilbay M (Antihistamine) and Ossopan Active (Immunity booster) into the Respiratory and GP/CP segments, respectively. During the year 2021-22, the Human Pharma Division (Undertaking) of Company was transferred, as a going concern, on a slump sale basis, for a consideration of Rs.805 crores to M/s BSV Pharma Private Limited (BSV), with effect from 9th May, 2022. Two new products, viz., Chirocyst DS and PCO 360 were launched under Ventura Division during 2021-22. The launch of Sponge Wipes and Ultra-scrubbers widened the portfolio into the Good Home Business division during the year. During the year 2022-23, Company launched the improved Skore 4.0 version with a new packaging and also added lubricants to the range into Protective Devices Business. It recommenced manufacturing operations at the Virudhunagar facility.

TTK Healthcare Ltd News Hub

News

TTK Healthcare to conduct AGM

TTK Healthcare announced that the Annual General Meeting(AGM) of the company will be held ...

Read more

29 May 202413:53

News

Board of TTK Healthcare recommends Final Dividend

TTK Healthcare announced that the Board of Directors of the Company at its meeting held on...

Read more

24 May 202415:56

News

TTK Healthcare to discuss results

TTK Healthcare will hold a meeting of the Board of Directors of the Company on 24 May 2024...

Read more

03 May 202417:01

News

TTK Healthcare to discuss results

TTK Healthcare will hold a meeting of the Board of Directors of the Company on 2 February ...

Read more

03 Jan 202412:03

News

TTK Healthcare to hold board meeting

TTK Healthcare will hold a meeting of the Board of Directors of the Company on 3 November ...

Read more

05 Oct 202311:16

News

TTK Healthcare schedules board meeting

TTK Healthcare will hold a meeting of the Board of Directors of the Company on 1 August 20...

Read more

15 Jul 202309:44

Product Composition by Percentage (Revenue)

FAQs for PE of TTK Healthcare Ltd

What is TTK Healthcare Ltd current share price?

The current market price of TTK Healthcare Ltd as of June 20, 2024 is ₹1482.45.

What is TTK Healthcare Ltd's market cap?

TTK Healthcare Ltd's market capitalisation stood at ₹2,067 Cr as of June 20, 2024

What are TTK Healthcare Ltd's total net assets?

According to TTK Healthcare Ltd's most recent financial filings, the company's net assets total ₹1070.6 Cr.

Is TTK Healthcare Ltd making a profit or loss?

TTK Healthcare Ltd's net Profit as of June 20, 2024 is close to ₹62 Cr.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199